Bioprosthetic Total Artificial Heart Implantation Does Not Induce Chronic Inflammation

ASAIO J. 2022 Nov 1;68(11):e173-e178. doi: 10.1097/MAT.0000000000001820. Epub 2022 Oct 12.

Abstract

The Aeson total artificial heart (A-TAH) has been developed for patients at risk of death from biventricular failure. We aimed to assess the inflammatory status in nine subjects implanted with the A-TAH in kinetics over one year. Laboratory assessment of leukocyte counts, inflammatory cytokines assay, and peripheral blood mononuclear cell collection before and after A-TAH implantation. Leukocyte counts were not significantly modulated according to time after A-TAH implantation (coefficient of the linear mixed effect model with 95% CI, -0.05 (-0.71 to -0.61); p = 0.44). We explored inflammatory cytokine after A-TAH and did not observe, at any time, a modified profile compared to pre-implantation values (all p -values > 0.05). Finally, we compared the distribution of circulating immune cell subpopulations identified based on sequential expression patterns for multiple clusters of differentiation. None of the population explored had significant modulation during the 12-month follow-up (all p -values > 0.05). In conclusion, using a cytokine multiplex assay combined with a flow cytometry approach, we demonstrated the absence of inflammatory signals in peripheral blood over a period of 12 months following A-TAH implantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines
  • Heart Failure* / surgery
  • Heart Transplantation* / adverse effects
  • Heart, Artificial* / adverse effects
  • Humans
  • Inflammation / etiology
  • Leukocytes, Mononuclear

Substances

  • Cytokines